Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.

被引：2
|
作者：
Hillmen, P
Skotnicki, AB
Robak, T
Mayer, J
Jaksic, B
Vukovic, V
Weitman, S
机构：
[1] Leeds Gen Infirm, PL-90131 Wakefield, England
[2] Jagiellonian Univ, Krakow, Poland
[3] Med Univ Lodz, Lodz, Poland
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[6] Ilex Pharmaceut LP, San Antonio, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2505.2505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2505
引用
收藏
页码：687A / 687A
页数：1
相关论文
共 50 条
  • [31] THE EFFICACY OF FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION IN UNTREATED VS PRETREATED PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
    Milosevic, V.
    Bogunovic, M.
    Jankovic, S.
    Antic, D.
    Tomin, D.
    Todorovic, M.
    Kurtovic, N. Kraguljac
    Jovanovic, M. Perunicic
    Bogdanovic, A.
    Mihaljevic, B.
    Gotic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 527 - 527
  • [32] EFFICACY AND SAFETY OF FRONT-LINE TREATMENT WITH IBRUTINIB AND RITUXIMAB IN UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). FIRST REPORT OF THE GIMEMA LLC1114 STUDY
    Mauro, F. R.
    Molica, S.
    Paoloni, F.
    Reda, G.
    Trentin, L.
    Marchetti, M.
    Pietrasanta, D.
    Coscia, M.
    Marasca, R.
    Sportoletti, P.
    Gaidano, G.
    Orsucci, L.
    Stelitano, C.
    Di Renzo, N.
    Liberati, M.
    Gottardi, D.
    Re, F.
    Ilariucci, F.
    Zinzani, P. L.
    Mannina, D.
    Gozzetti, A.
    Molinari, A. L.
    Gentile, M.
    Chiarenza, A.
    Laurenti, L.
    Varettoni, M.
    Ibatici, A.
    Murru, R.
    Tani, M.
    De Propris, M. S.
    Del Giudice, I.
    Della Starza, I.
    Raponi, S.
    Nanni, M.
    Fazi, P.
    Crea, E.
    Neri, A.
    Specchia, G.
    Guarini, A.
    Cuneo, A.
    Foa, R.
    HAEMATOLOGICA, 2019, 104 : 18 - 19
  • [33] EFFICACY AND SAFETY OF BENDAMUSTINE IN COMBINATION WITH RITUXIMAB FOR ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. AN ITALIAN RETROSPECTIVE MULTICENTER STUDY
    Laurenti, L.
    Autore, F.
    Innocenti, I.
    Vannata, B.
    Cantonetti, M.
    Del Principe, M. I.
    Mauro, F. R.
    Borza, P. Anticoli
    Bongarzoni, V.
    Ciolli, S.
    Boncompagni, R.
    Sciume, M.
    Vincenti, D.
    Ghio, F.
    Cecconi, N.
    Pitini, V.
    Mondello, P.
    Cariccio, M. R. Lanza
    Gozzetti, A.
    D'Arena, G.
    Murru, R.
    Piccirillo, N.
    Petrini, M.
    Cortelezzi, A.
    Del Poeta, G.
    Foa, R.
    Sica, S.
    HAEMATOLOGICA, 2014, 99 : 324 - 325
  • [34] Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'
    Mauro, Francesca Romana
    Reda, Gianluigi
    Arena, Valentina
    Trentin, Livio
    Coscia, Marta
    Sportoletti, Paolo
    Laurenti, Luca
    Gaidano, Gianluca
    Marasca, Roberto
    Orsucci, Lorella
    Murru, Roberta
    Stelitano, Caterina
    Ilariucci, Fiorella
    Mannina, Donato
    Massaia, Massimo
    Rigolin, Gian Matteo
    Scarfo, Lydia
    Marchetti, Monia
    Levato, Luciano
    Tani, Monica
    Arcari, Annalisa
    Musuraca, Gerardo
    Deodato, Marina
    Galieni, Piero
    Califano, Catello
    Gottardi, Daniela
    Liberati, Anna Marina
    Pietrasanta, Daniela
    Molica, Stefano
    Cassin, Ramona
    Visentin, Andrea
    Vitale, Candida
    Lapietra, Gianfranco
    Della Starza, Irene
    De Propris, Maria Stefania
    Raponi, Sara
    Nanni, Mauro
    Del Giudice, Ilaria
    Giuliani, Giorgia
    Vignetti, Marco
    Guarini, Anna
    Albano, Francesco
    Neri, Antonino
    Cuneo, Antonio
    Foa, Robin
    BLOOD, 2020, 136
  • [35] A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia
    Zittoun, R
    de Witte, T
    De Cataldo
    Delmer
    Gandra
    Haak
    Ho
    Jaksic
    Jehn
    Louwagie
    Peetermans
    Sonneveld
    Stryckmans
    Willemze
    Zittoun
    Zwierzina
    Jaksic
    Delmer
    Suciu
    Solbu
    HEMATOLOGY AND CELL THERAPY, 1999, 41 (03) : 127 - 136
  • [36] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
    Chanan-Khan, A.
    Egyed, M.
    Robak, T.
    Martinelli de Oliveira, F. A.
    Echeveste, M. A.
    Dolan, S.
    Desjardins, P.
    Blonski, J. Z.
    Mei, J.
    Golany, N.
    Zhang, J.
    Gribben, J. G.
    LEUKEMIA, 2017, 31 (05) : 1240 - 1243
  • [37] Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Ishizawa, Kenichi
    Fukuhara, Noriko
    Nakaseko, Chiaki
    Chiba, Shigeru
    Ogura, Michinori
    Okamoto, Akihiko
    Sunaga, Yoshinori
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (01) : 54 - 60
  • [38] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
    A Chanan-Khan
    M Egyed
    T Robak
    F A Martinelli de Oliveira
    M A Echeveste
    S Dolan
    P Desjardins
    J Z Blonski
    J Mei
    N Golany
    J Zhang
    J G Gribben
    Leukemia, 2017, 31 : 1240 - 1243
  • [39] Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Trelle, S
    Schnell, R
    Jensen, M
    Staib, P
    Schinköthe, T
    Stützer, H
    Rech, J
    Gramatzki, M
    Aulitzky, W
    Hasan, I
    Josting, A
    Hallek, M
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7024 - 7031
  • [40] Fludarabine vs high dose continuous chlorambucil: Interim analysis of a randomized phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL).
    Jaksic, B
    Delmer, A
    Brugiatelli, M
    Suciu, S
    Baumelou, E
    Roozendaal, KJ
    Wijermans, PW
    Jehn, U
    Teixeira, A
    Peeters, E
    Solbu, G
    Zittoun, R
    Willemze, R
    BLOOD, 1996, 88 (10) : 2342 - 2342
12345